Search results for intismeran
Industry
Moderna, Merck personalised mRNA cancer vaccine cuts melanoma recurrence or death risk by 42%
A personalised mRNA cancer vaccine being co-developed by Moderna and Merck reduced the risk of recurrence or death in melanoma patients by 42%, the report said. In a phase 3 trial involving 1,137 patients who had tumours removed by surgery, those receiving the vaccine intismeran with Merck\'s Keytruda outperformed a Keytruda-plus-placebo group. The companies are discussing approval procedures with regulators, with detailed results due at a European oncology meeting in Madrid.
Industry
Moderna jumps nearly 7% ahead of Nasdaq 100 inclusion; Citi warns of \'sell\'
Moderna shares jumped nearly 7% ahead of its scheduled inclusion in the Nasdaq 100 before the market opens on Oct. 9, closing at $203.21. The stock neared its 52-week high after rising to $205.77 intraday. Tokenised shares also gained, though they trade separately from Nasdaq hours. Moderna began management changes, with COO Juan Andres returning to a newly created role and CTO and quality chief Jerh Collins retiring. Citi downgraded the stock to sell.
Industry
Moderna shares surge 177 percent after success in phase 3 trial for mRNA cancer vaccine
Moderna shares jumped about 177 percent in a single day after the company reported positive results from the first phase 3 clinical trial of a personalised mRNA-based cancer treatment. Moderna said its intismeran autogene, used with Merck\'s Keytruda, met the main endpoints in the INTerpath-001 trial in patients with stage 2B to 4 melanoma after tumour removal surgery. Merck shares also rose. Short sellers\' losses widened to about $4.8 billion.